Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use Disorder and Alcohol-related Disorders (UT2)

Funding Opportunity PAR-15-153 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) directed to Small Business Technology Transfer (STTR) applicants is dedicated to the development of therapeutic agents for disorders that fall under the mission of NIAAA.An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the Small Business Technology Transfer (STTR) clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding